Says Austedo IRA price negotiations in-line with forecast. Says fundamentals of Austedo “very strong.” Expects to build momentum with biosimilars in Europe.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva says terminated exclusive discussions with select buyer for TAPI
- Teva says ‘clear path’ to 30% operating margin by 2027
- Teva says not moving forward with discussions for sale of TAPI
- Teva says net debt/EBITDA below 3.0x for first time since 2016
- Teva sees Austedo sales greater than $2.5B in 2027